Q3 2022 Earnings Forecast for Oak Street Health, Inc. Issued By William Blair (NYSE:OSH)

Oak Street Health, Inc. (NYSE:OSH – Get Rating) – Stock analysts at William Blair decreased their Q3 2022 earnings estimates for Oak Street Health in a report released on Tuesday, August 2nd. William Blair analyst R. Daniels now forecasts that the company will earn ($0.62) per share for the quarter, down from their prior estimate of ($0.61). The consensus estimate for Oak Street Health’s current full-year earnings is ($2.17) per share. William Blair also issued estimates for Oak Street Health’s FY2022 earnings at ($2.36) EPS, Q1 2023 earnings at ($0.36) EPS, Q2 2023 earnings at ($0.44) EPS, Q3 2023 earnings at ($0.40) EPS, Q4 2023 earnings at ($0.42) EPS and FY2023 earnings at ($1.60) EPS.

Oak Street Health (NYSE:OSH – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Oak Street Health had a negative return on equity of 716.26% and a negative net margin of 27.11%. The company had revenue of $513.80 million for the quarter, compared to analyst estimates of $506.82 million. During the same quarter in the prior year, the company posted ($0.29) earnings per share. The business’s revenue was up 73.2% on a year-over-year basis.

Other equities research analysts have also issued research reports about the stock. Sanford C. Bernstein began coverage on shares of Oak Street Health in a report on Thursday, May 26th. They set an “outperform” rating and a $26.00 target price for the company. UBS Group upped their target price on shares of Oak Street Health from $26.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday. Stifel Nicolaus upped their target price on shares of Oak Street Health from $25.00 to $35.00 in a report on Wednesday, July 27th. SVB Leerink upped their target price on shares of Oak Street Health from $23.00 to $32.00 and gave the stock a “market perform” rating in a report on Thursday. Finally, Barclays upped their price objective on shares of Oak Street Health from $27.00 to $31.00 and gave the company an “overweight” rating in a report on Tuesday, April 19th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Oak Street Health currently has a consensus rating of “Moderate Buy” and an average target price of $35.50.

Oak Street Health Price Performance

Oak Street Health stock opened at $30.29 on Friday. Oak Street Health has a 52-week low of $13.29 and a 52-week high of $64.75. The firm has a market capitalization of $7.30 billion, a price-to-earnings ratio of -13.77 and a beta of 3.05. The company has a fifty day simple moving average of $21.54 and a 200-day simple moving average of $20.69. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 16.10.

Institutional Trading of Oak Street Health

Several hedge funds have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas increased its stake in Oak Street Health by 18.7% in the fourth quarter. Teacher Retirement System of Texas now owns 18,399 shares of the company’s stock valued at $610,000 after purchasing an additional 2,894 shares during the last quarter. Fifth Third Bancorp purchased a new position in Oak Street Health in the first quarter valued at approximately $46,000. Baird Financial Group Inc. increased its stake in Oak Street Health by 9.6% in the fourth quarter. Baird Financial Group Inc. now owns 28,947 shares of the company’s stock valued at $959,000 after purchasing an additional 2,537 shares during the last quarter. Ellevest Inc. grew its position in shares of Oak Street Health by 9.7% during the first quarter. Ellevest Inc. now owns 74,274 shares of the company’s stock worth $1,996,000 after acquiring an additional 6,594 shares during the last quarter. Finally, CWM LLC purchased a new position in shares of Oak Street Health during the fourth quarter worth approximately $851,000. Institutional investors and hedge funds own 91.42% of the company’s stock.

Insider Transactions at Oak Street Health

In other news, COO Brian Clem sold 40,000 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $30.00, for a total transaction of $1,200,000.00. Following the sale, the chief operating officer now owns 596,468 shares of the company’s stock, valued at $17,894,040. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Brian Clem sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $30.00, for a total value of $1,200,000.00. Following the sale, the chief operating officer now owns 596,468 shares of the company’s stock, valued at $17,894,040. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Geoffrey M. Price sold 96,568 shares of the firm’s stock in a transaction that occurred on Tuesday, June 28th. The shares were sold at an average price of $18.56, for a total transaction of $1,792,302.08. Following the completion of the sale, the insider now directly owns 1,796,702 shares in the company, valued at approximately $33,346,789.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,014,413 shares of company stock valued at $25,854,151. 11.40% of the stock is currently owned by corporate insiders.

Oak Street Health Company Profile

(Get Rating)

Oak Street Health, Inc, together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2021, it operated 129 centers in 19 states, including Illinois, Michigan, Pennsylvania, Ohio, and Texas.